Holly is responsible for providing project strategy, direction and high-quality HEOR and access solutions for clients.
Holly has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, having begun working in the field in 2012. She has led numerous successful HTA submissions, including to NICE, SMC and AWMSG in the UK, as well as in several countries across Europe, and has attended and represented pharmaceutical companies at NICE appraisal committee meetings.
Holly has conducted over 75 HEOR projects, including systematic literature reviews, early and HTA-ready cost-effectiveness and budget impact models, feasibility assessments and indirect comparisons, and statistical analyses such as survival and HRQoL analyses. She has also managed a range of value communication materials, including user guides and technical reports, and published in several journals and conferences demonstrating her knowledge in oncology, haematology, and antimicrobials.